Intraocular Microbiota Screening for Dry AMD Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) lack effective therapies for the dry form, and the environmental factors triggering local inflammation in AMD pathology are not well understood, necessitating improved methods for assessing and treating intraocular diseases.
Innovation Solution
The development of screening methods and animal models that identify candidate therapeutics by culturing specific intraocular microbiota, such as Bacillus megaterium, to inhibit their growth, and using these models to test compounds for efficacy in treating AMD and other eye diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for AMD, then wet AMD can be controlled with anti-VEGF therapies, but dry AMD has no approved therapy and environmental factors triggering inflammation remain unclear
Solution Approach 1:
The patent introduces intraocular microbiota as an intermediary factor that mediates between environmental triggers and AMD pathology. By identifying specific bacteria (e.g., Bacillus megaterium) as potential culprits, the study bridges the gap between unknown environmental factors and the inflammatory processes causing drusen formation, providing a testable hypothesis for both wet and dry AMD mechanisms
Solution Approach 2:
The patent creates animal models (macaque monkeys) that replicate human AMD pathology to study microbial involvement. These models serve as copies of the human condition, allowing researchers to manipulate and observe the effects of specific microorganisms on disease progression without direct human experimentation, thereby advancing both treatment development and mechanistic understanding
2Device complexity
If the intraocular environment is considered sterile, then traditional treatment approaches remain simple, but pathogenic microorganisms cannot be identified and targeted
Solution Approach 1:
The patent converts the previously assumed sterile status of the intraocular environment into a beneficial discovery by identifying pathogenic microorganisms. This shift from sterility to controlled microbial presence allows for targeted antibiotic therapies and probiotic interventions, transforming an unknown harmful factor into a identifiable and treatable condition
Solution Approach 2:
The patent changes the fundamental parameter of intraocular environment from sterile to non-sterile by detecting and quantifying specific microorganisms. This parameter change enables the development of microbial load monitoring, antibiotic susceptibility testing, and microbiota-modulating therapies, fundamentally altering how AMD is approached and treated
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of candidate therapeutics that can inhibit the growth of pathogenic microorganisms associated with AMD, potentially leading to effective treatments for both dry and wet forms of the disease, and provides insights into the infectious etiology of AMD.
Implementation Method 1
a) culturing a microorganism in a suitable culture medium in the presence of a test compound
Data Source
AI summary
Provided herein are screening methods and animal models related to intraocular diseases such as age-related macular degeneration (AMD), for example, for identifying candidate therapeutics for treating or preventing eye diseases, such as AMD. Also provided herein are compounds/compositions that are useful for killing or inhibiting the growth of a microorganism, such as Bacillus megaterium. Further provided herein are methods of using the compounds/compositions for treating infections with a microorganism, such as Bacillus megaterium and for treating or preventing diseases or disorders associated with such infections, such as AMD.